A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt plc; Questcor Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 20 Oct 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
    • 14 Apr 2014 Planned end date changed to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top